BGIM
VIR icon

Brandywine Global Investment Management’s Vir Biotechnology VIR Stock Holding History

Brandywine Global Investment Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-211,970
Closed -$5.36M – 769
2022
Q4 		$5.36M Buy
+211,970
New +$5.2M 0.04% 364

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Brandywine Global Investment Management's VIR Position: Q1 2023 in Review

Brandywine Global Investment Management sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 211,970 shares — an estimated $5.36M sold.

Brandywine Global Investment Management first reported a position in VIR in Q4 2022 and held it in 1 quarter. The position peaked at $5.36M in Q4 2022. 232 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Brandywine Global Investment Management reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Brandywine Global Investment Management sold 211,970 Vir Biotechnology shares in Q1 2023, an estimated $5.36M.
  • Brandywine Global Investment Management first reported a position in Vir Biotechnology in Q4 2022 and held it in 1 quarter.
  • Brandywine Global Investment Management's Vir Biotechnology position peaked at $5.36M in Q4 2022.
  • 232 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Brandywine Global Investment Management's 13F filing for Q1 2023, filed 12 May 2023.